Friday, 16 Feb 2018

PsA/SpA

Datesort ascending Type Title Save
08 Feb 2018 News Recurrent Uveitis Increases the Risk of Ankylosing Spondylitis
05 Feb 2018 Social Opioids in Ankylosing spondylitis tend to be used for more subjective measures and not for objective inflammatory dz; also more likely to be using anxiolytic, hypnotic, antidepressant, and muscle relaxant medications. https://t.co/FcNpEzSZeZ
01 Feb 2018 News Opioid Use in Ankylosing Spondylitis
31 Jan 2018 Social Checkout Cush and the RheumNow Panel #ACR17 video discussing highlights from ACR 2017 in San Diego. https://t.co/OI3BYocnsy
28 Jan 2018 Social RAPID AxSpA study shows certolizumab Rx had 81% of AS without Xray progress) after 4 years (same 79% as secukinumab MEASURE 1 study). https://t.co/twW0PdmsDJ
23 Jan 2018 News Cimzia Limits Xray Progression in Axial Spondyloarthritis
22 Jan 2018 News Apremilast’s Rapid Onset in Psoriatic Arthritis
22 Jan 2018 Social Price of 6 mos of Psoriasis Rx: Guselkumab $29k; Taltz $28.6k; Humira $26.6k; $Enbrel 26.6k; Cosentyx $26.5k; Stelara $19k; Remicade $14k; Inflectra $11.3k; Renflexix $9k https://t.co/JoDA01agbz
18 Jan 2018 Social RT @ARD_BMJ: Evaluation of #efficacy of #apremilast in a phaseIIIb #RCT outlined fast response after week 2, with continuing efficacy over…
16 Jan 2018 News Salt Drives Gut-Brain Connection via IL-17
09 Jan 2018 Social JAMA/Med Letter review on Guselkumab (Tremfya) in Psoriasis. An IL-23 inhibitor, 100 mg SC given at wk 0, 4, then q8 weeks. https://t.co/DRcjCY8dqT
05 Jan 2018 Social Check out Dr. Artie Kavanaughs #ACR17 video review of new PsA treatments and outcome measures from ACR17 meeting. https://t.co/TgfVFDTh1i
02 Jan 2018 News MEASURE 3 Study - Anti-IL17 Benefits Persist in Spine Disease
30 Dec 2017 Social RT @ARD_BMJ: Inequity in biological DMARDs uptake for #spondyloarthritis across the globe: results from the ASAS-COMOSPA study https://t.co…
29 Dec 2017 Social Causes of Dactylitis = PsA, AS, SpA, reactive arthritis, MCTD, PSS, TB, syphilis, JIA, Sarcoid https://t.co/nhotKuYF2n
28 Dec 2017 News Therapeutic Update: 5 Questions on FDA Hearing for Tofacitinib in PsA (Best of 2017)
26 Dec 2017 Social FDA approves Xeljanz (tofacitinib) for use in adults with psoriatic arthritis, alone or in combo w/ MTX/DMARDs. But warns agains combining with biologics, cyclosporine or azathioprine as these have not been studied. https://t.co/MWgIp8uuUw
22 Dec 2017 Social 320 kids with juvenile PsA from CARRA shows 1 in 5 w/ JPsA are obese and > one-third were overweight. https://t.co/cZE0cHl68g
22 Dec 2017 Social SPIRIT-P1 study of Taltz (IXE) in PsA shows that after initial 24 blind, PBO & ADA pts rerandomized to IXE q2 or q4 wks==ACR20/50/70 of 69%/55%/39% for q2wk and 69%/53%/40% for q4wk at 1 yr. https://t.co/IPg1Hf7VoT
21 Dec 2017 Social Swedish analysis of 38,702 AS/SpA/PsA pts (vs 200,417 gen population) shows Biological-naïve AS/PsA /SpA have no incr risk of TB risk (OR 1.2; 0.5 to 2.7); but biologic use incr risk of TB (OR 7.5) https://t.co/zqPpxLZk5q